Chromosomal microarray analysis reveals many gene variants of unknown significance. The uncertainty about these variants—might they be deleterious or are they benign?—complicates genetic counseling.
Shivan J. Mehta, MD, MBA and David A. Asch, MD, MBA
Outcome-based payment more closely aligns payments with what patients want, which is better health rather than more health care. But these approaches remain challenging to implement.
Addicts quickly learn the diagnoses that cannot be definitively confirmed or ruled out by examinations or test results but that elicit prescriptions for opioid pain management.
The physician must consider the potential benefits of the new procedure and then determine, through discussion with the patient, what value the patient places on those specific benefits.
Ruth M. Farrell, MD, MA, Holly Pederson, MD, and Shilpa Padia, MD
Though they claim to, direct-to-consumer genetic tests may not correctly identify an individual's ancestral background, and thus may overstate or understate one's risk for heritable disease.
Allan B. Peetz, MD, Nicholas Sadovnikoff, MD, and Michael F. O’Connor, MD
Because of their serious medical conditions and the nature of the treatments, patients who are candidates for extracorporeal life support may not be able to give properly informed consent for the treatment.
AMA J Ethics. 2015;17(3):236-242. doi:
10.1001/journalofethics.2015.17.3.stas1-1503
Survey of faculty physicians at the University of Pennsylvania led to a list of proposals for health care reforms beyond those included in the Affordable Care Act.
AMA J Ethics. 2015;17(7):680-688. doi:
10.1001/journalofethics.2015.17.7.sect2-1507.
J. Brian Szender, MD, MS and Shashikant B. Lele, MD
The estimated reduction in risk of ovarian cancer for any woman undergoing opportunistic removal of the Fallopian tubes is up to 50 percent, but whether removal is more beneficial than ligation has not been established.
AMA J Ethics. 2015;17(9):843-848. doi:
10.1001/journalofethics.2015.17.9.stas1-1509.